CD274 and triple-negative breast carcinoma: Atezolizumab, (Tecentriq, Genentech, Inc.), formerly known as MPDL3280A, is a fully human IgG1 antibody directed to PD-L1, indicated for the treatment of urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC) and melanoma.